Wednesday, December 21, 2011

Amgen & Watson team up to develop oncology biosimilars

With the belief that there will be an official FDA ruling on biosimilars soon, many companies are making preparations to join the market.  Recently, partnership between Amgen and Watson Pharma to develop oncology biosimilars was announced.

According to Genetic Engineering & Biotechnology News, Amgen will be responsible for developing, manufacturing and commercializing the biosimialrs.  Watson will provide $400 million of support for in co-development costs and will also bring their expertise in commercializing and marketing specialty Pharmaceuticals and generics.  

What do you believe a partnership like this means for the future of biosimilars?

Share this article with your social network, just click below to share now!

No comments :

Post a Comment